feed,title,long_url,short_url
Benzinga,"Eli Lilly's Q3 Performance Shows Diabetes Drug Strength, But Cuts Annual Profit Guidance Related To Recent Acquisitions",https://benzinga.com/general/biotech/23/11/35563592/eli-lillys-q3-performance-shows-diabetes-drug-strength-but-cuts-annual-profit-guidance-related-to,https://da.gd/rYGCt9
